Journal of Research in Pharmacy Practice

The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: A pilot study

Authors

. Farahnaz Fatemi Naini 1
. Alireza Vaez Shooshtari 2
. Bahareh Ebrahimi 3
. Razieh Molaei 4

1 Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

2 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

3 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Cell and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Abstract
Objective: Pseudocatalase/superoxide dismutase (PSD) is a topical gel considered 
having therapeutic effects in vitiligo. This study was designed to evaluate the efficacy of 
this combination in vitiligo.
Methods: This was a pilot randomized, double‑blind, placebo‑controlled trial on 46 
symmetrical vitiligo lesions of limbs in 23 patients referring to dermatology clinics, 
Isfahan, Iran in 2010. Patients were received this formula or placebo gels for the right 
and left lesions. Lesion area and degree of pigmentation were assessed at baseline, 2, 4, 
and 6 months.
Findings: There were no significant changes in lesion area and perifollicular pigmentation 
in each group (P > 0.05).
Conclusion: The results indicated no significant therapeutic effect for PSD in vitiligo.

Keywords

Pseudocatalase/superoxide dismutase
efficacy
vitiligo

 

 

  1. Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 
    2009;360:160‑9.
    2. Miniati A, Weng Z, Zhang B, Stratigos AJ, Nicolaidou E, 
    Theoharides TC. Neuro‑immuno‑endocrine processes 
    in vitiligo pathogenesis. Int J Immunopathol Pharmacol 
    2012;25:1‑7.
    3. Patel NS, Paghdal KV, Cohen GF. Advanced treatment 
    modalities for vitiligo. Dermatol Surg 2012;38:381‑91.
    4. Colucci R, Lotti T, Moretti S. Vitiligo: An update on current 
    pharmacotherapy and future directions. Expert Opin 
    Pharmacother 2012;13:1885‑99.
    5. Hazneci E, Karabulut AB, Oztürk C, Batçioğlu K, Doğan G, 
    Karaca S, et al. A comparative study of superoxide dismutase, 
    catalase, and glutathione peroxidase activities and nitrate 
    levels in vitiligo patients. Int J Dermatol 2005;44:636‑40.
    6. Arican O, Kurutas EB. Oxidative stress in the blood of patients 
    with active localized vitiligo. Acta Dermatovenerol Alp 
    Panonica Adriat 2008;17:12‑6.
    7. Gawkrodger DJ. Pseudocatalase and narrowband ultraviolet B 
    for vitiligo: Clearing the picture. Br J Dermatol 2009;161:721‑2.
    8. Yuksel EP, Aydin F, Senturk N, Canturk T, Turanli AY. 
    Comparison of the efficacy of narrow band ultraviolet B and 
    narrow band ultraviolet B plus topical catalase‑superoxide 
    dismutase treatment in vitiligo patients. Eur J Dermatol 
    2009;19:341‑4.
    9. Bakis‑Petsoglou S, Le Guay JL, Wittal R. A randomized, 
    double‑blinded, placebo‑controlled trial of pseudocatalase 
    cream and narrowband ultraviolet B in the treatment of 
    vitiligo. Br J Dermatol 2009;161:910‑7.
    10. Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella 
    R. A double‑blind, randomized trial of 0.05% betamethasone 
    vs. topical catalase/dismutase superoxide in vitiligo. J Eur 
    Acad Dermatol Venereol 2008;22:1359‑64.
  2. 11. Schallreuter KU, Rokos H. Vitix‑ A new treatment for vitiligo? 
    Int J Dermatol 2005;44:969‑70.
    12. Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for 
    the treatment of vitilgo vulgaris: An open label pilot clinical 
    trial. BMC Complement Altern Med 2011;11:21
Journal of Research in Pharmacy Practice
Volume 1, Issue 2
November 2012
Pages 77-80

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us